Pharma in Brief

AUGUST 5, 2020

DESCOVY contains a combination of tenofovir alafenamide ( TAF ) hemifumarate and emtricitabine. GENVOYA is a designated “innovative drug” in respect to TAF pursuant to the data protection provisions of the Food and Drug Regulations , CRC, c 870 ( Data Protection Regulations ). Background. Minister of Health’s Decision.

Containment 52

Containment Drugs Regulation Medicine 52

BioTech 365

OCTOBER 22, 2020

This Announcement Contains Inside Information for the Purposes of Article 7 of Regulation (EU) No 596/2014 LONDON, Oct. 22, 2020 (GLOBE NEWSWIRE) — Abcam plc (AIM: ABC) (“Abcam”), a global leader in the supply of life science research tools, announces … Continue reading →

Life Science 40

Life Science Containment Regulation Research 40

Pharma in Brief

JANUARY 26, 2022

The Federal Court has confirmed that issues of infringement, including by inducement, may be decided by summary trial in an infringement action under the Patented Medicines (Notice of Compliance) Regulations (the Regulations ). Background. the PMS Product ). In that case, Manson J. Knowledge of influence.

Regulation 52

Regulation Trials Production Compliance 52

The Pharma Data

NOVEMBER 10, 2020

Weiner, chairman of the scientific advisory board of Tiziana Life Sciences, commented: “We understand that this will be the first-ever study with ‘take-home’ capsules of any mAb for immunotherapies for human diseases. This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Life Science 40

Life Science Clinical Trials Clinical Trials Trials 40

Pharma in Brief

JANUARY 7, 2024

Whether Florida is able to import drugs from Canada, including in light of Canadian regulations controlling drug exports, remains to be seen. As we reported , the export regulations first issued as an interim order in November 2020, in response to the FDA publishing the US Importation Rule in October 2020. 01.014.13).

Drugs 52

Drugs Regulation FDA Approval Manufacturing 52

Pharma in Brief

OCTOBER 29, 2020

Regulatory amendments to the Food and Drug Regulations ( FDR ) and the Natural Health Products Regulations ( NHPR ) were published in Canada Gazette (Part II) on October 14, 2020. any drug identification number or natural product number previously issued for the drug has not been cancelled for safety reasons.

Regulation 40

Regulation Sales Drugs Manufacturing 40

Pharma in Brief

APRIL 13, 2021

The Food and Drug Regulations ( FDR ) have been amended to allow for continued expedited review of COVID-19 drugs (including vaccines) while transitioning to authorizations by way of a full notice of compliance ( NOC ) under the FDR. Health Canada has also published a guidance document that contains additional information for drug sponsors.

Regulation 52

Regulation Drugs Vaccination Vaccine 52

Pharma in Brief

MAY 29, 2023

The CSP Guidance was revised to reflect amendments to the definition of “authorization for sale” in the Certificate of Supplementary Protection Regulations ( CSP Regulations ) and to reflect changes to Health Canada’s administrative practices. Certificate of Supplementary Protection Regulations , SOR/2017-165

Regulation 59

Regulation Sales Clinical Trials Clinical Trials 59

pharmaphorum

FEBRUARY 25, 2022

The past two years have shone a spotlight on the UK life sciences industry. These efforts, as Nadhim Zahawi rightly said when he was Vaccines Minister, have led to the life sciences and pharma industry becoming a UK national treasure. An industry that will forever play a greater role in our everyday lives.

Life Science 98

Life Science Vaccination Vaccine Pharmacy 98

XTalks

MAY 13, 2022

A container closure system consists of all the packaging components that contain and protect a pharmaceutical product. Container Closure Systems. A container closure system protects the product from environmental conditions, safeguarding a product’s purity, strength, safety and efficacy.

Packaging 98

Packaging Packaging Containment Production 98

Pharma in Brief

JANUARY 24, 2021

The Canadian pharma and life sciences space saw many developments in 2020, despite and in some cases because of the COVID-19 pandemic. The year saw the first trials and decisions in actions under the new Patented Medicines (Notice of Compliance) Regulations ( PM(NOC) Regulations ). Introduction.

Life Science 52

Life Science Regulation Medicine Drugs 52

Pharma in Brief

JULY 28, 2020

On July 10, 2020, the Federal Court issued a decision in a judicial review under the Certificate of Supplementary Protection Regulations ( CSP Regulations ). JULUCA ® is a fixed-dose combination ( FDC ) drug product containing the medicinal ingredients dolutegravir and rilpivirine ( JULUCA ).

Production 52

Production Containment Drugs Regulation 52

Drug Discovery World

DECEMBER 14, 2023

The Federation of American Scientists (FAS) has published five policy recommendations to address the challenges of artificial intelligence (AI) in life sciences. Significant effort has gone into establishing frameworks to evaluate and reduce risks from ‘foundation’ AI models (i.e.,

Scientist 52

Scientist DNA Life Science Development 52

XTalks

AUGUST 16, 2022

Health regulators in the UK have become the first in the world to approve Moderna’s next generation COVID-19 vaccine booster that includes targeting of the Omicron variant. 1) when compared to a 50 µg booster dose of mRNA-1273 in baseline seronegative participants.

Vaccination 98

Vaccination Vaccine Antibody Regulation 98

XTalks

FEBRUARY 21, 2022

The BioNTainer is housed in shipping containers equipped with state-of-the-art technology for producing the mRNA vaccines from start to finish, except for the final fill-and-finish step that will be performed by local manufacturing partners. Each module contains six standard sized containers, which measure 2.6

Vaccination 105

Vaccination Vaccine Production Manufacturing 105

Drug Discovery World

SEPTEMBER 28, 2023

In fact, the endometrial fluid contains peptides that may protect against a variety of fungi, bacteria, viruses, and other pathogens 4. Probiotics offer a relatively straightforward, minimally regulated avenue to correcting dysbiosis, and a significant market exists already.

Clinical Trials 64

Clinical Trials Clinical Trials Regulation Bacteria 64

Pharma in Brief

JANUARY 9, 2022

These policy initiatives included reforms to the Patented Medicine Prices Review Board ( PMPRB ), the Patented Medicines (Notice of Compliance Regulations) ( PM(NOC) Regulations ), the Patent Rules , and other regulatory matters at Health Canada. Proposed amendments to the PM(NOC) Regulations were also introduced in 2021.

Regulation 52

Regulation Manufacturing Medicine Drugs 52

pharmaphorum

FEBRUARY 4, 2021

That’s why CIOs and CTOs working within the life sciences industry need to include Salesforce org management as a key component of their standard operating procedures. As such, many in the life sciences industry view Salesforce as more than just a CRM, and are running the entire enterprise with it.

Compliance 104

Compliance Life Science HR Development 104

Pharma in Brief

MARCH 2, 2021

of the Patented Medicines (Notice of Compliance) Regulations ( Regulations ) is not subject to the 45-day limitation period familiar to patentees asserting infringement of listed patents under subsection 6(1). the Plaintiffs ) are involved in litigation under the Regulations against Sandoz Canada Inc. of the Regulations.

Regulation 52

Regulation Compliance Containment Medicine 52

Pharma in Brief

SEPTEMBER 8, 2022

On August 17, 2022, the Federal Court dismissed applications for judicial review regarding the product-specificity requirements for addressing patents listed on the Patent Register under the Patented Medicines (Notice of Compliance) Regulations (the Regulations ). Background. Subsection 5(1) is DIN-specific.

Marketing 52

Marketing Drugs Regulation Compliance 52

Pharma in Brief

JULY 5, 2021

The Federal Court of Appeal ( FCA ) has confirmed that in an infringement action under the Patented Medicines (Notice of Compliance) Regulations , the “second person” ( i.e. , generic/biosimilar) is not precluded from pleading invalidity allegations in its Statement of Defence beyond those that were raised in its notice of allegation ( NOA ).

Regulation 52

Regulation Compliance Containment Branding 52

pharmaphorum

AUGUST 31, 2021

For the innovators and early adopters of the life sciences industry, engineering a regulatory-grade ECA can be daunting. The industry has looked to regulators for guidance, and the Food and Drug Administration (FDA) has been quick to respond. It is true that RWD contains more potential bias as a result.

Clinical Trials 75

Clinical Trials Clinical Trials Life Science Trials 75

Pharma in Brief

MARCH 21, 2022

Also reported was Health Canada’s intention to introduce transition regulations, which would have ended the expedited IO authorization pathway but extended current IO authorizations so that industry could meet therequirements for converting their IO approvals to medical device licenses under the Medical Devices Regulations (the Regulations ).

Sales 52

Sales Regulation Manufacturing Licensing 52

XTalks

AUGUST 3, 2021

Johnson and Johnson has faced thousands of lawsuits over its iconic baby powder, which people claim the company knew for decades contained asbestos. Talc and asbestos are often found together in nature, which is why mined talc can contain the carcinogen.

Containment 98

Containment Production Contamination Marketing 98

Pharma in Brief

JUNE 14, 2022

The Federal Court has allowed an infringement action concerning a macitentan product under the Patented Medicines (Notice of Compliance) Regulations (the Regulations ). OPSUMIT® is a tablet containing macitentan. Background. Janssen Inc. Janssen Inc. Sandoz Canada Inc. Sandoz ) sought approval for a generic macitentan product.

Containment 52

Containment In-Vivo Regulation Production 52

The Pharma Data

JANUARY 12, 2021

13, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

Pharma in Brief

JUNE 9, 2021

of the Food and Drug Regulations (the Data Protection Provisions ). The dispute arose due to two concurrent New Drug Submissions ( NDSs ) filed by different drug manufacturers for products containing amifampridine. Catalyst ) filed an NDS for FIRDAPSE, which contains amifampridine. Background.

Containment 52

Containment Production Compliance Drugs 52

pharmaphorum

DECEMBER 15, 2022

Co-chaired by Lord James O’Shaughnessy and Professor Mike Bewick, former deputy national medical director of NHS England (present online), the NHS Innovation and Life Sciences Commission Report launch took place at One Great George Street, Westminster, on 12th December 2022. The UK as a powerhouse of research.

Life Science 95

Life Science Medicine Clinical Trials Clinical Trials 95

XTalks

APRIL 24, 2023

Early and ongoing engagement with regulators greatly helps clinical development planning. Scientific advice meetings with regulators help ensure the trial design and gene therapy manufacturing will meet regulatory expectations. As a result, there are several EU regulations and directives to follow.

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

The Pharma Data

OCTOBER 26, 2020

Novasep provides cost-effective and sustainable manufacturing solutions for the life sciences industries. This press release contains certain forward-looking statements concerning Sensorion and its business. The communication of this press release in certain countries may constitute a violation of local laws and regulations.

Gene Therapy 52

Gene Therapy Gene Manufacturing Production 52

Pharma in Brief

DECEMBER 17, 2023

According to the Minister, JAMP’s new drug submission for SIMLANDI did not engage the Patented Medicines (Notice of Compliance) Regulations ( Regulations ). As a consequence, the Court’s recent decision of December 4, 2023 does not concern the Regulations , but rather parallel actions brought under the Patent Act. A-203-22).

Antibody 52

Antibody Production Regulation Marketing 52

Pharma in Brief

SEPTEMBER 5, 2023

If classified instead as edible cannabis, Jolts would exceed the THC content per immediate container permitted by the Cannabis Regulations. Organigram classified Jolts as cannabis extract in notices of new cannabis product to Health Canada.

Compliance 52

Compliance Production Containment Regulation 52

Pharma in Brief

MARCH 9, 2022

The Federal Court has decided an infringement action concerning risedronate products under the Patented Medicines (Notice of Compliance) Regulations (the Regulations ). ACTONEL DR® is an enteric-coated delayed release tablet containing risedronate and ethylene-daimine-tetraacetic acid ( EDTA ). Background. Allergan Inc.

Production 52

Production Regulation Containment Compliance 52

Pharma in Brief

APRIL 19, 2022

The Federal Court has allowed an infringement action concerning sitagliptin phosphate monohydrate products under the Patented Medicines (Notice of Compliance) Regulations (the Regulations ). In reaching its decision, the Court provided substantive guidance on hearsay evidence in infringement actions under the Regulations.

Regulation 52

Regulation Production Compliance Containment 52

The Pharma Data

AUGUST 18, 2020

The drug repositioning pillar builds on Johnson & Johnson’s ongoing partnership with the prestigious Rega Institute at KU Leuven in Belgium, where a team of scientists are screening molecule libraries containing thousands of existing compounds to determine if they have potential as COVID-19 treatments.

Development 52

Development Research Containment Production 52

XTalks

JUNE 28, 2023

It is injected into a patient’s muscle tissue. The FDA approval came after several delays and a narrow advisory committee vote of eight to six in favor of the gene therapy’s risk-benefit profile.

Gene Therapy 98

Gene Therapy Gene Protein FDA Approval 98

Pharma in Brief

JULY 18, 2022

The Federal Court has allowed a second infringement action concerning a macitentan product under the Patented Medicines (Notice of Compliance) Regulations (the Regulations ). The Court found that the defendant would induce infringement of claims relating to combination treatment if it were allowed to market its macitentan product.

Production 52

Production Containment Regulation Compliance 52